Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Fineline Cube Jul 13, 2026
Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Fineline Cube Jul 13, 2026
Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Fineline Cube Jul 13, 2026
Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Fineline Cube Jul 13, 2026
Company Deals

Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform

Fineline Cube Oct 11, 2024

Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...

Company Deals

XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery

Fineline Cube Oct 11, 2024

XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...

Company Drug

Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology

Fineline Cube Oct 11, 2024

Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...

Company Drug

Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard

Fineline Cube Oct 11, 2024

Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...

Company Drug

Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...

Company Drug

Jiangsu Hengrui Secures FDA Nod for Generic Abraxane, Strengthening Oncology Portfolio

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has achieved a first in the US market...

Company Medical Device

Roche’s VENTANA CLDN18 Assay Receives EU Approval, Enhances Targeted Therapy Options for Gastric Cancer

Fineline Cube Oct 11, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) has secured CE Mark approval in the European Union for...

Company Drug

Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment

Fineline Cube Oct 11, 2024

Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...

Company

Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand

Fineline Cube Oct 11, 2024

Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...

Legal / IP Policy / Regulatory

China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

Fineline Cube Oct 11, 2024

The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...

Company Drug Medical Device

Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China

Fineline Cube Oct 11, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...

Company Medical Device

Sino Medical Sciences Secures NMPA Nod for Balloon Guided Catheter to Aid Vascular Procedures

Fineline Cube Oct 10, 2024

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received marketing...

Company Deals

Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors

Fineline Cube Oct 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Deals

Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics’ Recombinant Polio Vaccine

Fineline Cube Oct 10, 2024

The Bill & Melinda Gates Foundation has committed USD 17 million to support the development...

Company Drug

InnoCare Pharma’s ICP-488 Shows Promising Results in Phase II Psoriasis Study

Fineline Cube Oct 10, 2024

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...

Company Drug

Ascletis Pharma Faces US Import Ban for NASH Drugs ASC41 and ASC43F in Trade Secrets Dispute

Fineline Cube Oct 10, 2024

China’s Ascletis Pharma Inc. (HKG: 1672) is navigating legal proceedings involving its oral thyroid hormone...

Company Deals

Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment

Fineline Cube Oct 10, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced a capital injection of RMB 220...

Company

Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit

Fineline Cube Oct 10, 2024

Effective October 10, 2024, Yan Qiong will join the management team of Eli Lilly (NYSE:...

Policy / Regulatory

Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services

Fineline Cube Oct 10, 2024

The Shanghai Municipal Health Commission, along with 13 other bureaus, has issued a local adaptation...

Company Drug

InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment

Fineline Cube Oct 10, 2024

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...

Posts pagination

1 … 314 315 316 … 693

Recent updates

  • Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer
  • Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
  • Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma
  • Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan
  • Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Company Drug

Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.